A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Exclusion Criteria

• •Evidence of clinically significant cardiovascular, hepatic, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities or had a known history of any GI surgery or cholecystectomy.
• •Clinically significant illness within 8 weeks or had a clinically significant infection within 4 weeks prior to the first dose.
• •Clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations.
• •Systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
• •The subject has a clinically significant ECG abnormality, or had a family history of prolonged QTc syndrome or sudden death.
• •A history of smoking or use of nicotine-containing substances within the previous 2 months.
• •A history of drug or alcohol misuse in the previous 6 months.
• •Has been diagnosed with acquired immune deficiency syndrome (AIDS) or are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
• •Has participated in a clinical trial of other drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the subject is currently enrolled in another clinical trial.
• •Has received blood or blood products within 4 weeks, or donated blood or blood products within 8 weeks.
• •Has used any over-the-counter (OTC) medications or prescription drugs within 2 weeks.